Epidemiology of Invasive Meningococcal Disease Worldwide from 2010-2019: a Literature Review

Overview

Journal Epidemiol Infect

Publisher Cambridge University Press

Specialties Infectious Diseases
Public Health

Date 2023 Apr 13

PMID 37052295

Authors

Carmen Pardo de Santayana

Myint Tin Tin Htar

Jamie Findlow

Paul Balmer

Affiliations

Soon will be listed here.

Abstract

The epidemiology of invasive meningococcal disease (IMD) is unpredictable, varies by region and age group and continuously evolves. This review aimed to describe trends in the incidence of IMD and serogroup distribution by age group and global region over time. Data were extracted from 90 subnational, national and multinational grey literature surveillance reports and 22 published articles related to the burden of IMD from 2010 to 2019 in 77 countries. The global incidence of IMD was generally low, with substantial variability between regions in circulating disease-causing serogroups. The highest incidence was usually observed in infants, generally followed by young children and adolescents/young adults, as well as older adults in some countries. Globally, serogroup B was a predominant cause of IMD in most countries. Additionally, there was a notable increase in the number of IMD cases caused by serogroups W and Y from 2010 to 2019 in several regions, highlighting the unpredictable and dynamic nature of the disease. Overall, serogroups A, B, C, W and Y were responsible for the vast majority of IMD cases, despite the availability of vaccines to prevent disease due to these serogroups.

Citing Articles

Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA.

Shah H, Jutlla G, Herrera-Restrepo O, Graham J, Grace M, Khan S Pharmacoeconomics. 2025; .

PMID: 40072776 DOI: 10.1007/s40273-025-01477-0.

Invasive Meningococcal Disease in the Post-COVID World: Patterns of Disease Rebound.

Findlow J, Htar M, Villena R, Balmer P Vaccines (Basel). 2025; 13(2).

PMID: 40006712 PMC: 11861802. DOI: 10.3390/vaccines13020165.

Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.

Martinon-Torres F, Lamberth E, Martinez S, Salamanca de la Cueva I, Zolotas L, Oladipupo I Hum Vaccin Immunother. 2025; 21(1):2463194.

PMID: 39993937 PMC: 11853628. DOI: 10.1080/21645515.2025.2463194.

A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix Vaccine When Given to Healthy Infants at 3 and 12 Months of Age.

Koski S, Martinon-Torres F, Ramet M, Zolotas L, Newton R, Maansson R Infect Dis Ther. 2025; 14(2):463-481.

PMID: 39883399 PMC: 11829884. DOI: 10.1007/s40121-024-01098-8.

Management and prevention of Neisseria meningitidis and Neisseria gonorrhoeae infections in the context of evolving antimicrobial resistance trends.

Marshall H, Molina J, Berlaimont V, Mulgirigama A, Sohn W, Bercot B Eur J Clin Microbiol Infect Dis. 2024; 44(2):233-250.

PMID: 39601904 PMC: 11754362. DOI: 10.1007/s10096-024-04968-8.

References

Omoleke S, Alabi O, Shuaib F, Braka F, Tegegne S, Umeh G . Environmental, economic and socio-cultural risk factors of recurrent seasonal epidemics of cerebrospinal meningitis in Kebbi state, northwestern Nigeria: a qualitative approach. BMC Public Health. 2018; 18(Suppl 4):1318. PMC: 6292165. DOI: 10.1186/s12889-018-6196-9. View

Li J, Wu D, Yin Z, Li Y . [Analysis of epidemic characteristics for meningococcal meningitis in China during 2015-2017]. Zhonghua Yu Fang Yi Xue Za Zhi. 2019; 53(2):159-163. DOI: 10.3760/cma.j.issn.0253-9624.2019.02.007. View

Munguambe A, Castro Cardoso De Almeida A, Nhantumbo A, Come C, Zimba T, Langa J . Characterization of strains of Neisseria meningitidis causing meningococcal meningitis in Mozambique, 2014: Implications for vaccination against meningococcal meningitis. PLoS One. 2018; 13(8):e0197390. PMC: 6082507. DOI: 10.1371/journal.pone.0197390. View

Htar M, Jackson S, Balmer P, Serra L, Vyse A, Slack M . Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs. BMC Public Health. 2020; 20(1):1890. PMC: 7724720. DOI: 10.1186/s12889-020-09946-1. View

Thompson M, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L . Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006; 367(9508):397-403. DOI: 10.1016/S0140-6736(06)67932-4. View

Araya P, Fernandez J, Del Canto F, Seoane M, Ibarz-Pavon A, Barra G . Neisseria meningitidis ST-11 clonal complex, Chile 2012. Emerg Infect Dis. 2015; 21(2):339-41. PMC: 4313638. DOI: 10.3201/eid2102.140746. View

Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga J, De Serres G, De Wals P . Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019; 37(31):4243-4245. DOI: 10.1016/j.vaccine.2019.06.021. View

Booy R, Gentile A, Nissen M, Whelan J, Abitbol V . Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2018; 15(2):470-480. PMC: 6505668. DOI: 10.1080/21645515.2018.1532248. View

Read R . Neisseria meningitidis and meningococcal disease: recent discoveries and innovations. Curr Opin Infect Dis. 2019; 32(6):601-608. DOI: 10.1097/QCO.0000000000000606. View

10.

Rosenstein N, Perkins B, Stephens D, Popovic T, Hughes J . Meningococcal disease. N Engl J Med. 2001; 344(18):1378-88. DOI: 10.1056/NEJM200105033441807. View

11.

Nuttens C, Findlow J, Balmer P, Swerdlow D, Htar M . Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. Euro Surveill. 2022; 27(3). PMC: 8804660. DOI: 10.2807/1560-7917.ES.2022.27.3.2002075. View

12.

Purmohamad A, Abasi E, Azimi T, Hosseini S, Safari H, Nasiri M . Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis. Microb Pathog. 2019; 134:103571. DOI: 10.1016/j.micpath.2019.103571. View

13.

Azzari C, Moriondo M, Nieddu F, Guarnieri V, Lodi L, Canessa C . Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014-2018). Vaccines (Basel). 2020; 8(3). PMC: 7563708. DOI: 10.3390/vaccines8030469. View

14.

Christensen H, May M, Bowen L, Hickman M, Trotter C . Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10(12):853-61. DOI: 10.1016/S1473-3099(10)70251-6. View

15.

Tan L, Carlone G, Borrow R . Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010; 362(16):1511-20. DOI: 10.1056/NEJMra0906357. View

16.

McMillan M, Wang B, Koehler A, Sullivan T, Marshall H . Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents. Clin Infect Dis. 2021; 73(1):e233-e237. DOI: 10.1093/cid/ciaa1636. View

17.

Husain E, Barakat M, Al-Saleh M . Trends and variations in the epidemiology of meningococcal disease in Kuwait 1987-2013. J Infect Public Health. 2015; 8(5):441-7. DOI: 10.1016/j.jiph.2015.01.009. View

18.

Diallo A, Soeters H, Yameogo I, Sawadogo G, Ake F, Lingani C . Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign. PLoS One. 2017; 12(11):e0187466. PMC: 5667755. DOI: 10.1371/journal.pone.0187466. View

19.

Parikh S, Campbell H, Bettinger J, Harrison L, Marshall H, Martinon-Torres F . The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020; 81(4):483-498. DOI: 10.1016/j.jinf.2020.05.079. View

20.

Harrison L, Trotter C, Ramsay M . Global epidemiology of meningococcal disease. Vaccine. 2009; 27 Suppl 2:B51-63. DOI: 10.1016/j.vaccine.2009.04.063. View